Author(s): Ghosh M,Brancato SJ, Agarwal PK, Apolo AB
Purpose of review: Greater understanding of the biology and genetics of urothelial carcinoma is helping to identify and define the role of molecules and pathways appropriate for novel-targeted therapies. Here, we review the targeted therapies that have been reported or are in ongoing urothelial carcinoma clinical trials, and highlight molecular targets characterized in preclinical and clinical studies.
Recent findings: Trials in nonmuscle-invasive bladder cancer are evaluating the role of immunotherapy and agents targeting vascular endothelial growth factor (VEGF) or fibroblast growth factor receptor-3. In muscle-invasive bladder cancer, neoadjuvant studies have focused on combining VEGF agents with chemotherapy; adjuvant studies are testing vaccines and agents targeting the human epidermal growth factor receptor 2, p53, and Hsp27. In the first-line treatment of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte antigen 4, Hsp27, and p53 are novel targets in clinical trials. The majority of targeted agents studied in urothelial carcinoma are in the second-line setting; new targets include CD105, polo-like kinase-1, phosphatidylinositide 3-kinases (PI3K), transforming growth factor β receptor/activin receptor-like kinase β, estrogen receptor, and the hepatocyte growth factor receptor (HGFR or MET).
Summary: Development of targeted therapies for urothelial carcinoma is still in early stages, consequently there have been no major therapeutic advances to date. However, greater understanding of urothelial carcinoma and solid tumor biology has resulted in a proliferation of clinical trials that could lead to significant advances in treatment strategies.
Referred From: https://pubmed.ncbi.nlm.nih.gov/24685646/
Author(s): Ghafouri-Fard S,Nekoohesh L, Motevaseli E
Author(s): Ploeg M,Aben KK, Kiemeney LA
Author(s): Cheung G,Sahai A, Billia M, Dasgupta P, Khan MS
Author(s): Biagioli MC, Fernandez DC, Spiess PE, Wilder RB
Author(s): Zhu XL, Ai ZH, Wang J, Xu YL, Teng YC
Author(s): Wang HF, Wang JS
Author(s): Schiffer E,Vlahou A, Petrolekas A, Stravodimos K, Tauber R, et al.
Author(s): Chin L, Hahn WC, Getz G, Meyerson M
Author(s): Horvath S, Dong J
Author(s): Langfelder P, Horvath S
Author(s): Kristensen VN,Lingjærde OC,Russnes HG,Vollan HK,Frigessi A, et al.
Author(s): Stranger BE, Stahl EA, Raj T
Author(s): Gautier L, Cope L, Bolstad BM, Irizarry RA
Author(s): Smyth, GK
Author(s): Song L, Langfelder P, Horvath S
Author(s): Zhang W, Zang Z, Song Y, Yang H, Yin Q
Author(s): Mason MJ, Fan G, Plath K, Zhou Q, Horvath S
Author(s): Zhang B, Horvath S
Author(s): Yip AM, Horvath S
Author(s): Li L, Shiga M, Ching WK, Mamitsuka H
Author(s): Xiao X, Moreno-Moral A, Rotival M, Bottolo L, Petretto E
Author(s): Puniya BL, Kulshreshtha D, Verma SP, Kumar S, Ramachandran S
Author(s): Frantzi M,Makridakis M, Vlahou A
Author(s): Zeng T, Sun SY, Wang Y, Zhu H, Chen L
Author(s): Liu R, Wang X, Aihara K, Chen L
Author(s): He D, Liu ZP, Honda M, Kaneko S, Chen L
Author(s): Lezon-Geyda K,Najfeld V, Johnson EM
Author(s): De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, et al.
Author(s): Gout S,Brambilla E, Boudria A, Drissi R, Lantuejoul S, et al.
Author(s): An Y, Zhou Y, Ren G, Tian Q, Lu Y, et al.
Author(s): Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV
Author(s): Wyce A,Degenhardt Y, Bai Y, Le B, Korenchuk S, et al.
Author(s): Chan WK,Bhalla AD, Le Hir H, Nguyen LS, Huang L, et al.
Author(s): Karam R,Carvalho J, Bruno I, Graziadio C, Senz J, et al.
Author(s): Wang J,Peng X, Peng W, Wu FX
Author(s): Arum CJ,Anderssen E, Tømmerås K, Lundgren S, Chen D, et al.
Author(s): Oppezzo P,Dighiero G
Author(s): Boulalas I,Zaravinos A, Karyotis I, Delakas D, Spandidos DA
Author(s): Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, et al.
Author(s): Fernández-Medarde A, Santos E